New York is currently home to 4498 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML
Recruiting
This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation, Mixed Phenotype Acute Leukemia, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma
Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys
Recruiting
The goal of this follow-up study is to learn about long-term patient survival and graft function in highly sensitized patients who have received desensitization treatment with imlifidase or standard of care (SoC) in order to enable kidney transplantation in clinical study ConfIdeS (20-HMedIdeS-17, NCT04935177).
Gender:
ALL
Ages:
All
Trial Updated:
06/03/2025
Locations: New York University (NYU) Langone Transplant Institute, NYU Langone Health, New York, New York
Conditions: Kidney Transplantation in Highly Sensitized Patients
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
Recruiting
The primary objective of this study is to assess the impact of bethanechol therapy on R0 resection rates. The safety objective will be assessment of the safety and tolerability of bethanechol in combination with gemcitabine and nab-paclitaxel. The exploratory objective will be to evaluate genomic biomarkers associated with parasympathetic stimulation in pancreatic cancer, and the ability to reduce tumor growth rate.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Columbia University Medical Center, New York, New York
Conditions: Pancreas Cancer
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/03/2025
Locations: South Shore Neurologic Associates, Patchogue, New York
Conditions: Relapsing Multiple Sclerosis
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/03/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Relapsing Multiple Sclerosis
Cardiogenic Shock Working Group Registry
Recruiting
The Cardiogenic Shock Working Group is a multicenter registry where we collect de-identified clinical variables from the medical records and follow-up phone calls of shock patients from multiple institutions and centralize this data to a single registry for analysis of clinical outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Cardiogenic Shock
CD4CAR for CD4+ Leukemia and Lymphoma
Recruiting
This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells. Funding Source - FDA OOPD
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/03/2025
Locations: Albert Einstein Health Network, New York, New York
Conditions: T-cell Lymphoma, T-cell Leukemia
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Recruiting
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
06/03/2025
Locations: The Children's Hospital at Montefiore, Bronx, New York
Conditions: Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
COBRA: Cancer, Older Adults, Balance and Resistance Activities
Recruiting
The purpose of this study is to find out whether an 8-week digital health promotion program called COBRA is a safe and practical (feasible) option for older adults with cancer/OAC.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
06/02/2025
Locations: Memorial Sloan Kettering Suffolk-Commack (Consent Only), Commack, New York
Conditions: Primary Cancer, Metastatic Cancer, Cancer
A Study of ZL-1310 in Participants With Selected Solid Tumors
Recruiting
A Phase Ib/II, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Zai Lab Site 2002, New York, New York
Conditions: Solid Tumors
Motor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds)
Recruiting
The primary goal of this study is to validate motor and functional outcomes and refine clinical trial strategies for pediatric-onset FSHD
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
06/02/2025
Locations: University of Rochester, Rochester, New York
Conditions: Muscular Dystrophy, Facioscapulohumeral
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
Recruiting
The study has 2 parts, Phase 1a and Phase 1b. The goal of Phase 1a is to gather safety, PK and initial efficacy data for 225Ac-ABD147 to better understand best doses for patients with small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) of the lung following platinum-based chemotherapy. An initial group of patients will also be given an experimental imaging agent called 111In-ABD147 to help understand where ABD147 goes in the body. The goal of Phase 1b is to gather add... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung